Topical therapy is underused in patients with ulcerative colitis

Journal of Crohn's and Colitis

Volumn 8, Issue 1, 2014, Pages 56-63

  Seibold, F ^a,f   Fournier, N ^b   Beglinger, C ^c   Mottet, C ^d   Pittet, V ^b   Rogler, G ^e  

^a Departement Gastroenterologie   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d HÔpital neuchâtelois   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

Enema; Proctitis; Quality of life; Rectal foam; Topical therapy; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADOLESCENT; ADULT; AGED; APPLICATION SITE PAIN; ARTICLE; ASTHMA; COLITIS; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PANCOLITIS; PANCREATITIS; PRIORITY JOURNAL; PROCTITIS; QUALITY OF LIFE; REMISSION; SHORT FORM 36; TOPICAL TREATMENT; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ENEMA; PROCTITIS; QUALITY OF LIFE; RECTAL FOAM; SIBDCS; SWISS INFLAMMATORY BOWEL DISEASE COHORT STUDY.; TOPICAL THERAPY; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADMINISTRATION, TOPICAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUDESONIDE; COLITIS, ULCERATIVE; ENEMA; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MESALAMINE; MIDDLE AGED; PROCTITIS; SEVERITY OF ILLNESS INDEX; SWITZERLAND; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84890117921     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.03.005     Document Type: Article

References (37)

1. Solberg I.C., Lygren I., Jahnsen J., et al. Clinical course during the first 10years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009, 44(4):431-440.
2. Gionchetti P., Amadini C., Rizzello F., et al. Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther 2002, 16(Suppl. 4):13-19.
3. Marshall J.K., Irvine E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997, 40(6):775-781.
4. Campieri M., Gionchetti P., Belluzzi A., et al. Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis. Dig Dis Sci 1987, 32(12 Suppl.):67S-70S.
5. Marshall J.K., Irvine E.J. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995, 9(3):293-300.
6. Campieri M., Gionchetti P., Belluzzi A., et al. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?. J Clin Gastroenterol 1988, 10(4):406-409.
7. Regueiro M., Loftus E.V., Steinhart A.H., et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006, 12(10):979-994.
8. Dignass A., Lindsay J.O., Sturm A., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: current management. J Crohns Colitis 2012 Dec, 6(10):991-1030.
9. Katz S., Lichtenstein G.R., Safdi M.A. 5-ASA dose-response: maximizing efficacy and adherence. Gastroenterol Hepatol (N Y) 2010, 6(2 Suppl. 3):1-16.
10. Prantera C., Rizzi M. 5-ASA in ulcerative colitis: improving treatment compliance. World J Gastroenterol 2009, 15:4353-4355.
11. Kane S.V., Brixner D., Rubin D.T., et al. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm 2008, 14:s2-s12.
12. Fernandez-Becker N.Q., Moss A.C. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs 2008, 68:1089-1103.
13. Hawthorne A.B., Rubin G., Ghosh S. Review article: medication non-adherence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008, 27:1157-1166.
14. Kane S.V. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006, 23:577-585.
15. Marshall J.K., Thabane M., Steinhart A.H., et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010, 1:CD004115.
16. James S.L., Irving P.M., Gearry R.B., et al. Management of distal ulcerative colitis: frequently asked questions analysis. Intern Med J 2008, 38:114-119.
17. Cortot A., Maetz D., Degoutte E., et al. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. Am J Gastroenterol 2008, 103:3106-3114.
18. Pokrotnieks J., Marlicz K., Paradowski L., et al. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 2000, 14:1191-1198.
19. Campieri M., Corbelli C., Gionchetti P., et al. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci 1992, 37:1890-1897.
20. Eliakim R., Tulassay Z., Kupcinskas L., et al. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther 2007, 26:1237-1249.
21. Mulder C.J., Fockens P., Meijer J.W., et al. Beclomethasone dipropionate (3mg) versus 5-aminosalicylic acid (2g) versus the combination of both (3mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996, 8:549-553.
22. Safdi M., DeMicco M., Sninsky C., et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997, 92:1867-1871.
23. Marshall J.K., Irvine E.J. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000, 95:1628-1636.
24. Rogler G. Medical management of ulcerative colitis. Dig Dis 2009, 27:542-549.
25. Travis S.P., Stange E.F., Lémann M., For the European Crohn's and Colitis Organisation (ECCO), et al. European evidence-based consensus on the management of ulcerative colitis: current management. Crohns Colitis 2008, 2:24-62.
26. Lakatos P.L., Lakatos L. Ulcerative proctitis: a review of pharmacotherapy and management. Expert Opin Pharmacother 2008, 9:741-749.
27. Reddy S.I., Friedman S., Telford J.J., et al. Are patients with inflammatory bowel disease receiving optimal care?. Am J Gastroenterol 2005, 100:1357-1361.
28. Pittet V., Juillerat P., Mottet C., et al. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study. Int J Epidemiol 2009, 38:922-931.
29. Casellas F., Vaquero E., Armengol J.R., et al. Practicality of 5-aminosalicylic suppositories for long-term treatment of inactive distal ulcerative colitis. Hepatogastroenterology 1999, 46:2343-2346.
30. D'Arienzo A., Panarese A., D'Armiento F.P., et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol 1990, 85:1079-1082.
31. D'Albasio G., Pacini F., Camarri E., et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997, 92:1143-1147.
32. Piodi L.P., Ulivieri F.M., Cermesoni L., et al. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 2004, 39:154-157.
33. Hartmann F., Stein J., BudMesa-Study Group Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther Aug 2010, 32(3):368-376. [Epub 2010 May 11].
34. Marteau P., Probert C.S., Lindgren S., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005, 54:960-965.
35. D'Haens G.R., Kovács A., Vergauwe P., et al. Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX® 9mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis Jun 2010, 4(2):153-160. [Epub 2009 Oct 24].
36. Ford A.C., Khan K.J., Sandborn W.J., et al. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol 2012, 10:513-519.
37. Lakatos L., Kiss L.S., David G., et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis 2011 Dec, 17(12):2558-2565. 10.1002/ibd.21607. Epub 2011 Jan 6.